SEC Company Response from AIM ImmunoTech Inc. (AIM) (CIK 0000946644) (AIM) — Jul 31, 2018
AIM ImmunoTech Inc. (AIM) (CIK 0000946644)
Date: July 31, 2018 · CIK: 0000946644 · Accession: 0001493152-18-010727
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226059
Letter
Re: Hemispherx Biopharma, Inc.
HEMISPHERX BIOPHARMA, INC.
1617 JFK Boulevard
Philadelphia, Pennsylvania 19103
July 31, 2018
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20002
Registration Statement on Form S-3
(SEC filing No. 333-226059)
Acceleration Request
Requested Date: August 3, 2018
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Hemispherx Biopharma, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-226059) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Silverman Shin & Byrne PLLC, by calling Richard Feiner, Esq. at (646) 822-1170.
Very truly yours,
HEMISPHERX BIOPHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
HEMISPHERX BIOPHARMA, INC.
1617 JFK Boulevard
Philadelphia, Pennsylvania 19103
July 31, 2018
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20002
Re:
Hemispherx
Biopharma, Inc.
Registration
Statement on Form S-3
(SEC
filing No. 333-226059)
Acceleration
Request
Requested
Date: August 3, 2018
Requested
Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under
the Securities Act of 1933, as amended, Hemispherx Biopharma, Inc. (the “Company”) hereby requests that the above-referenced
Registration Statement on Form S-1 (File No. 333-226059) (the “Registration Statement”) be declared effective at the
“Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel
may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Once the Registration Statement
has been declared effective, please orally confirm that event with our counsel, Silverman Shin & Byrne PLLC, by calling Richard
Feiner, Esq. at (646) 822-1170.
Very truly yours,
HEMISPHERX BIOPHARMA, INC.
By:
/s/
Adam Pascale
Adam Pascale,
Chief Financial Officer
cc: Richard Feiner, Esq.